Amplitude Titration to Improve ECT Clinical Outcomes

Description

A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency

Conditions

Depression, ECT, Cognitive Change

Talk to us

Study Overview

On this page

Study Details

Study overview

A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency

Amplitude Titration to Improve ECT Clinical Outcomes Randomized Clinical Trial

Amplitude Titration to Improve ECT Clinical Outcomes

Condition
Depression
Intervention / Treatment

-

Contacts and Locations

Albuquerque

University of New Mexico Health Science Center, Albuquerque, New Mexico, United States, 87110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of major depressive disorder or bipolar II
  • * Clinical indications for ECT with right unilateral electrode placement
  • * Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)
  • * Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder)
  • * Current drug or alcohol use disorder (except for nicotine)
  • * Contraindications to MRI.

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of New Mexico,

Chris Abbott, MD, PRINCIPAL_INVESTIGATOR, University of New Mexico

Study Record Dates

2026-01-30